Document Detail


Activated protein C resistance determined with a thrombin generation-based test is associated with thrombotic events in patients with lupus anticoagulants.
MedLine Citation:
PMID:  17958739     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Several studies suggest that antiphospholipid antibodies interfere with the activity of activated protein C (APC). This acquired form of APC resistance has been proposed as a possible pathogenic mechanism underlying hypercoagulability associated with the antiphospholipid syndrome (APS). OBJECTIVES: We wanted to investigate the inhibitory effect of recombinant APC (rAPC) on ex vivo thrombin generation in plasma and the modification of this effect by the presence of lupus anticoagulants (LA). PATIENTS/METHODS: We analyzed plasmas from 81 patients with LA (52 patients fulfilling the criteria for the APS) and 91 controls. Percent inhibition of the endogenous thrombin potential (ETP) as a parameter of APC sensitivity was determined in plasmas using a thrombin generation-based APC resistance test probed with rAPC. All results were normalized using pooled normal plasma (PNP) as a reference. RESULTS: Normalized percent inhibition of ETP by APC was lower in patients with LA [61.4%, 95% confidence interval (CI) 45.8-74.5%] compared to controls (107.8%, 95% CI: 107.1-109.3%). In patients with LA and APS, median inhibition was lower than in patients with LA without APS (44.6%, 95% CI: 30.1-55.7% vs. 78.8%, 95% CI: 73.9-95.8%). This difference also persisted when patients on warfarin therapy were excluded from the APS subgroup. CONCLUSIONS: APC resistance can be demonstrated with a thrombin generation-based test in a majority of patients with the LA laboratory phenotype. A history of thrombotic events in patients with LA is associated with a stronger resistance to the anticoagulant effect of APC.
Authors:
S Liestøl; P M Sandset; M-C Mowinckel; F Wisløff
Related Documents :
11529629 - Cerebral atrophy related to corticotherapy in systemic lupus erythematosus (sle).
14626629 - The relationship between serum ferritin levels and disease activity in systemic lupus e...
11831119 - Systemic lupus erythematosus complicated by recurrent spontaneous pneumothorax--a case ...
19952069 - Efficacy and safety of cyclosporine a in patients with refractory systemic lupus erythe...
7389219 - Effects of corticosteroids on natural killer cell activity in systemic lupus erythemato...
10501419 - High disease activity at baseline does not prevent a remission in patients with systemi...
19638089 - Reflux profile of chinese gastroesophageal reflux disease patients with combined multic...
22364869 - First diagnostic criteria for atopic myelitis with special reference to discrimination ...
1967239 - Reflux esophagitis in patients with zollinger-ellison syndrome.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Journal of thrombosis and haemostasis : JTH     Volume:  5     ISSN:  1538-7933     ISO Abbreviation:  J. Thromb. Haemost.     Publication Date:  2007 Nov 
Date Detail:
Created Date:  2007-10-25     Completed Date:  2007-12-26     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101170508     Medline TA:  J Thromb Haemost     Country:  England    
Other Details:
Languages:  eng     Pagination:  2204-10     Citation Subset:  IM    
Affiliation:
Department of Hematology, Ullevål University Hospital, Faculty Division Ullevål University Hospital, University of Oslo, Oslo, Norway. sigurdli@ulrik.uio.no
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Activated Protein C Resistance / complications*
Adult
Antiphospholipid Syndrome / complications*
Blood Coagulation Tests
Case-Control Studies
Female
Humans
Lupus Coagulation Inhibitor / blood*
Male
Middle Aged
Protein C / pharmacology
Recombinant Proteins
Thrombin / pharmacology*
Thrombophilia / complications
Thrombosis / etiology*
Warfarin / pharmacology,  therapeutic use
Chemical
Reg. No./Substance:
0/Lupus Coagulation Inhibitor; 0/Protein C; 0/Recombinant Proteins; 81-81-2/Warfarin; EC 3.4.21.5/Thrombin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The G20210A prothrombin variant and the risk of venous thromboembolism or fetal loss in pregnant wom...
Next Document:  Thrombin-induced cell proliferation and platelet-derived growth factor-AB release from A172 human gl...